Serum CCL11 is significantly increased in IBD patients, considered to be associated with increased colonic eosinophils, and Ccl11-/- mice were found to be tolerant to DSS-induced colitis and to reduce the colonic tumor load induced by azomethine (AOM)-DSS, suggesting that CCL11 antibodies might be valuable for IBD treatment and cancer prevention [140]. This evidence concerns the gene CCL11 and cancer.